media – Page 9 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

HB0025 injection initiates Phase III clinical trial for endometrial cancer

Huahai Pharmaceutical(600521) announced on March 19 that its subsidiary, Shanghai Huaaotai Biotechnology Co., Ltd.Following the completion of the Phase II clinical trial and the pre-initiation meeting for the Phase III clinical trial with the Center for Drug Evaluation of the National Medical Products Administration, the company’s independently developed HB0025 injection will officially commence Phase III clinical trials for advanced/recurrent endometrial cancer. This trial will primarily evaluate the therapeutic efficacy, safety, and tolerability of HB0025 in combination with chemotherapy. To date, the company’s total R&D investment in the HB0025 project is approximately RMB 342 million. According to the announcement, HB0025 is an innovative anti-PD-L1/VEGF bispecific fusion protein that simultaneously targets the tumor immune escape pathway PD-L1 and the tumor angiogenesis pathway VEGF, possessing a dual anti-tumor mechanism of “immune enhancement + anti-angiogenesis”. Currently, there are no completely similar products on the market domestically or internationally. The development of this product will ...
- Source: drugdu
- 80
- March 19, 2026
Industry News | Bowang Pharmaceutical’s siRNA therapy granted Fast Track designation by the FDA

On March 16, Bowang Pharmaceutical announced that its investigational siRNA therapy BW-20805 received Fast Track designation from the U.S. FDA for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disorder that causes sudden, unpredictable swelling in different parts of the body. Severe cases can lead to laryngeal edema, with a mortality rate as high as approximately 40%. BW-20805 is an siRNA therapy targeting prokallikrein (PKK). By targeting PKK mRNA and inhibiting PKK gene expression, it holds promise for providing long-term flare prevention for patients with heart attack (HAE). PKK is currently a well-established therapeutic target in HAE treatment. Recent data presented by Bowang Pharmaceuticals at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting showed that BW-20805 significantly reduces plasma PKK levels and achieves a clinically significant reduction in HAE flare rates. Bowang Pharmaceuticals is currently conducting a Phase 2 clinical trial in adult HAE ...
- Source: drugdu
- 85
- March 19, 2026
Chongqing Yaoyou Pharmaceutical Receives Approval for 2 Billion Yuan Worth of Injectable Drugs

Moxifloxacin hydrochloride sodium chloride injection is an 8-methoxyfluoroquinolone antibiotic with broad-spectrum activity and bactericidal effects. It is suitable for acute bacterial sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia, complicated/uncomplicated skin and skin tissue infections, and complicated intra-abdominal infections caused by susceptible bacteria. According to data from Menet.com , Moxifloxacin Hydrochloride Sodium Chloride Injection is a Class B drug covered by the National Medical Insurance and a National Essential Medicines List. In 2024, its sales in China’s three major terminals and six major markets approached 2 billion yuan, recovering to the level before the implementation of the national centralized procurement policy. However, it experienced a certain degree of decline in the first three quarters of 2025. Sales of Moxifloxacin Hydrochloride Sodium Chloride Injection in China’s Three Major Terminals and Six Major Markets in Recent Years (Unit: RMB 10,000) Source: Menet Pattern Database Currently, more than 30 domestic companies have passed ...
- Source: drugdu
- 61
- March 19, 2026
Chinese Cell Therapy Company Secures Over 100 Million Yuan Seed Funding

Recently, SkyeThera Pharmaceuticals (Shanghai) Co., Ltd. (“SkyeThera” or the “Company”) announced the completion of a seed round financing totaling over 100 million yuan. The round was co-led by Hony Capital and PowerFong Health Fund, with participation from Su Venture Capital, Chenshu Investment, Yingxian Investment and Yida Capital. The proceeds will be mainly allocated to three core areas: the R&D of in vivo multi-target cell therapy candidates, the next-generation universal multi-target CAR-T products for the broad autoimmune disease field, and the development of multi-target CAR-T cell therapy products based on a new-generation rapid autologous manufacturing process. SkyeThera’s founding was driven by keen insights into deep-seated pain points in the cell therapy industry. Although CAR-T therapies have demonstrated remarkable efficacy in hematologic malignancies, they still face three major challenges in real-world clinical practice: high production costs, long manufacturing cycles, and patient relapse due to antigen escape. As an innovative company focused on ...
- Source: drugdu
- 85
- March 19, 2026
March 19, 2026, from the Wechat Public Account “Smart Pharma Hub”

On February 10, 2026, Galux announced the successful completion of a $29 million Series B financing (approximately 42 billion KRW). Following this round, the company’s total cumulative funding reached $47 million (around 68 billion KRW). The Series B round brought together a number of long-term and new institutional investors. Existing investors including InterVest, DAYLI Partners, and PATHWAY Investment participated in the round, while new investors comprised Yuanta Investment, Korea Development Bank (KDB), SL Investment, NCORE Ventures, SneakPeek Investments, Korea Investment & Securities, and Mirae Asset Securities. Galux previously completed an $18 million Series A financing in 2022 (approximately 21 billion KRW), which supported the upgrade of its AI platform and the enhancement of its R&D capabilities. Since then, the company has achieved multiple key R&D and commercial milestones. The successful completion of the Series B round further validates its execution capabilities and growth momentum. Dr. Sang-gyun Kim, Managing Director at ...
- Source: drugdu
- 164
- March 19, 2026
General Practice Conference & Exhibition

Organiser：Reed Exhibitions Australia Pty Ltd Time：May 15 – May 17, 2026 Address：14 Darling Dr, Sydney NSW 2000 Exhibition hall：Sydney Convention and Exhibition Centre Product range: Testing Instruments: Blood pressure and blood glucose monitors, electronic thermometers, blood oxygen detectors, one-drop blood testers, various testing reagents, cardiovascular detectors, blood lipid detectors, stethoscopes, sperm count testers, contraception devices, home electrocardiograms, health detectors, pedometers, and other home-use testing instruments. Health Products: Various health-oriented small home appliances; health textiles with functions such as nanotechnology, magnetic therapy, far-infrared, negative ions, tourmaline, and bamboo charcoal; sleep products, bedding, clothing, protective gear, accessories, and steam sauna series; nano-electrolysis multifunctional water makers, ionized water machines, direct drinking water machines, central water purification equipment, nano-ecological antibacterial cups, water treatment and environmental protection series; health-preserving activated cups, energy cups, wellness cups, and other health and wellness products. Nursing Equipment: Various rehabilitation and nursing equipment, barrier-free equipment, mobility aids, hearing and ...
- Source: drugdu
- 87
- March 19, 2026
Paliperidone API Receives Marketing Approval

PKU HealthCare announced on the evening of March 17 that it recently received the ” Chemical Raw Materials” certificate issued by the National Medical Products Administration. The drug marketing application approval notice was issued, and the submitted product “paliperidone (packaging specifications: 1kg/bag, 5kg/bag, 10kg/bag)” was approved for registration after review, meeting the relevant requirements for drug registration. Data shows that paliperidone is the main active metabolite of risperidone. It is a second-generation antipsychotic drug with strong control effects, high affinity, tolerability and efficacy. It is mainly used to treat schizophrenia in adults and adolescents aged 12-17 (weight ≥29Kg). PKU HealthCare stated that paliperidone raw material The approval will help the company further promote its “raw material and formulation integration” strategy, create synergies with formulation products, enhance its competitiveness in production cost control and supply chain stability, and have a positive effect on the company’s future performance. https://finance.eastmoney.com/a/202603173674705264.html
- Source: drugdu
- 84
- March 18, 2026
Subsidiary obtains registration certificate for antidepressant drug

March 17th – Jiuzhou PharmaceuticalThe company issued an announcement stating that its wholly-owned subsidiary, Jiuzhou Biopharmaceutical (Taizhou) Co., Ltd. (formerly Zhejiang Siwei Pharmaceutical Technology Co., Ltd.), received the Drug Registration Certificate for Vortioxetine Hydrobromide Tablets issued by the National Medical Products Administration. The approved drug is vortioxetine hydrobromide tablets, available in tablet form (5mg and 10mg) and classified as a Class 4 chemical drug. This drug is primarily used for the treatment of major depressive disorder (MDD) in adults. Vortioxetine hydrobromide tablets are manufactured by Lundbeck (Denmark) and Takeda (Japan).The product was jointly developed and approved for market launch in the United States in September 2013, and in China in November 2017. According to the announcement, the total sales (terminal price) of vortioxetine hydrobromide tablets in the domestic medical and retail markets in 2024 were approximately RMB 214 million. As of the date of the announcement, Jiuzhou Pharmaceutical ‘s cumulative ...
- Source: drugdu
- 81
- March 18, 2026
Fosun Pharma’s subsidiary, Junji Health, has received clinical trial approval from the National Medical Products Administration for its LBP-ShC4 product.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that its subsidiary, Shanghai Junji Health Technology Co., Ltd., has received approval from the National Medical Products Administration (NMPA) of China for its independently developed in vivo biological therapy product, LBP-ShC4, to conduct clinical trials in China. The product is intended for the treatment of androgenetic alopecia (AGA). Previously, clinical trials for the same indication were approved by the U.S. Food and Drug Administration (FDA) in May 2025. According to the announcement, as of February 2026, Fosun Pharmaceutical Group’s cumulative R&D investment in LBP-ShC4 was approximately RMB 20 million. Currently, there are no in vivo biological therapy products (including monotherapy or combination therapy) approved for the treatment of androgenetic alopecia globally. Fosun Pharmaceutical stated that LBP-ShC4 still needs to complete a series of clinical studies in China and obtain approval from the NMPA before it can be marketed. The company also cautioned that ...
- Source: drugdu
- 84
- March 18, 2026
A world first! my country achieves regenerated islet transplantation, opening a new path for diabetes treatment.

Reporters learned from the Center for Excellence in Molecular Cell Science (Institute of Biochemistry and Cell Biology), Chinese Academy of Sciences, that Professor Cheng Xin’s research group at the center, in collaboration with Professor Yin Hao’s team at the Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), recently achieved, for the first time internationally, minimally invasive transplantation of regenerated islets (E-islets) derived from autologous and allogeneic stem cells, enabling pancreatic islet function reconstruction and autonomous blood glucose regulation in patients with type 1 diabetes. The relevant findings have been published online in the international academic journal *The Lancet Diabetes & Endocrinology*. Diabetes is a chronic disease that seriously threatens the health of Chinese residents, with type 1 diabetes being most prevalent in children and adolescents. Due to autoimmune disorders and the body’s immune system’s abnormal attack and destruction of pancreatic beta cells, pancreatic function fails, insulin secretion is ...
- Source: drugdu
- 81
- March 18, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.